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Angiotensin converting enzyme gene I/D polymorphism in essential
hypertension and nephroangiosclerosis. An insertion/deletion (I/D) poly-
morphism of the angiotensin converting enzyme (ACE) gene significantly
influences circulating ACE levels and plays a role in the development of
target organ damage, that is, left ventricular hypertrophy in essential
hypertension (EH), and microalbuminuria in diabetes mellitus. We have
examined the role of the I/D polymorphism in essential hypertensive
patients with renal involvement. The study was divided in two independent
protocols. In protocol 1, we retrospectively analyzed the ACE genotypes in
37 essential hypertensive patients with a clinical and histopathological
diagnosis of nephroangiosclerosis. In protocol 2, ACE genotypes as well as
microalbuminuria and renal hemodynamic parameters were investigated
in 75 patients with EH with normal renal function and a strong family
history of hypertension. As control group, 75 healthy subjects with BP ,
130/85 mm Hg and no family history of cardiovascular diseases were
studied. The ACE variants were determined by PCR and the genotypes
were classified as DD, DI and II. In protocol 1, patients with nephroan-
giosclerosis displayed a significant difference in the genotype distribution
(57% DD, 27% DI, 16% II) when compared to the control population
(25% DD, 64% DI, 11% II; P , 0.001). There was no significant
difference in genotype distribution between hypertensive patients with
normal renal function (protocol 2; 33% DD, 59% DI, 8% II) and the
control group. There were no differences in age, blood pressure, mi-
croalbuminuria and duration of the disease among the three genotypes in
the EH group from protocol 2. Taken together, these findings suggest that
the DD genotype of ACE is associated with histopathologic-proven kidney
involvement in patients with EH and that this polymorphism could be a
potential genetic marker in hypertensives at risk of renal complications.
Arterial hypertension is the second most frequent cause of
end-stage renal disease in patients entering a chronic dialysis
program both in Europe and in the United States [1, 2]. Although
pharmacological treatment of essential hypertension (EH) has
decreased the incidence of cardiac and cerebral complications,
renal involvement in this disease has not been reduced to the
same proportion [1]. Therefore, besides high blood pressure (BP),
other factors have been considered in the pathogenesis of the
renal complications of hypertension.
The renin-angiotensin system (RAS) plays a central role in salt
and water homeostasis and in the maintenance of vascular tone.
This system acts both as a circulating hormonal system, and as a
local one as well, serving paracrine, autocrine and intracrine
functions. In addition to the renal hemodynamic and tubular
transport actions, the intrarenal RAS probably plays an important
role as regulator of mesangial and endothelial cell function, acting
as an inductor of cell growth [3]. There is a fair amount of
evidence, supported both by experimental and clinical studies,
that this system plays an important pathogenic role in the
development of renal damage in EH, that is, nephroangiosclero-
sis, and that this effect is not exclusively related to hemodynamic
factors [3, 4]. Specifically, transgenic animals expressing an addi-
tional renin gene show more rapid worsening of renal function
than those without the additional gene, despite similar BP levels
[5]. Moreover, recent gene transfer studies have shown that the
addition of the human angiotensinogen and renin genes to the rat
kidney induces glomerular sclerosis with no change in BP [6]. On
the other hand, the use of angiotensin converting enzyme (ACE)
inhibitors has been shown to have protective renal effects reduc-
ing the urinary protein excretion and slowing the progression of
renal failure in several pathologies, independently of their BP
lowering effect [3, 4]. About 15% of hypertensive patients show a
decline in the renal function, in many cases despite a good BP
control [7], pointing to an individual susceptibility in the devel-
opment of renal damage in these patients.
An insertion/deletion (I/D) polymorphism of the ACE gene has
been identified in humans [8, 10]. The ACE gene consists of 26
exons and spans 21 Kb on chromosome 17 [9], and the I/D
polymorphism is characterized by the presence or absence of a
287 base pair fragment in intron 16 resulting in three genotypes
(DD, DI and II) [8]. The physiological importance of the I/D
polymorphism relies on the fact that the DD genotype is associ-
ated with increased circulating [10] and tissue [11] ACE levels.
This genotype has also been linked to EH [12], and left ventricular
hypertrophy [13], although with varying results among popula-
tions [14, 15]. Relevant to the kidney, the DD genotype has more
recently been related to the development of nephropathy in
insulin and non-insulin dependent diabetes [16, 17], and to the
antiproteinuric efficacy of ACE inhibition in patients with pro-
teinuria [18]. Furthermore, it has recently been noticed that this
genotype is associated with the progression of renal insufficiency
in IgA nephropathy [19, 20]. However, there are no data about the
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possible role of this genetic polymorphism in proved renal dam-
age observed in EH. Therefore, we investigated whether the ACE




The study was approved by the local Ethics Committee and all
patients gave their written informed consent. The patients were
recruited from the outpatient clinic of the Renal Unit at Hospital
Clinic in Barcelona. In Protocol 1 we initially included in a
retrospective analysis 47 patients with EH and histologic diagnosis
of nephroangiosclerosis. The following inclusion criteria were
applied: (a) diagnosis of EH prior to the development of renal
insufficiency, (b) histopathologic diagnosis of nephroangiosclero-
sis [21], (c) age , 50 years, and (d) absence of diabetes mellitus.
Five patients were excluded because by careful analysis the
diagnosis was not unequivocal by clinical or pathological grounds
and good quality DNA could not be obtained for genotyping in
five additional patients. In Protocol 2, 75 treated essential hyper-
tensive patients were included. The following selection criteria
were applied: (a) diagnosis of moderate-severe EH with a systolic
BP .160 mm Hg and diastolic BP .100 mm Hg, (b) age between
25 and 65 years, (c) family history of hypertension in at least one
parent and one first degree relative, (d) absence of diabetes
mellitus, (e) body mass index , 30 kg/m2, and (f) alcohol intake ,
50 g/day. Patients on oral contraceptives were excluded. As a
control group 75 healthy subjects from the Hospital blood bank
with the following inclusion criteria were analyzed: (a) age
between 25 and 65 years, (b) systolic BP ,130 mm Hg and
diastolic BP , 85 mm Hg, and (c) no family history of cardiovas-
cular diseases (including hypertension, myocardial infarction or
stroke). This control group included 46 males and 29 females aged
40 6 1.2 years with a systolic blood pressure (SBP) of 116 6 1.2
mm Hg and diastolic blood pressure (DBP) of 70 6 1 mm Hg
(mean 6 SEM). All individuals included were Caucasian.
Evaluation of the renal profile
In patients from protocol 1, renal biopsies were performed at
our institution between 1975 and 1995 and were examined by the
same pathologist by optic and immunofluorescence microscopy.
Nephroangiosclerosis was diagnosed using widely accepted clini-
cal and pathologic criteria [21]. Renal function in hypertensive
patients from protocol 2 was evaluated by measuring plasma
creatinine, glomerular filtration rate (GFR), effective renal
plasma flow (ERPF) and filtration fraction (FF). GFR and ERPF
were measured by single shot clearance technique using intrave-
nous injection of 125I-thalamate and 131I-hippurate respectively.
Values were corrected for calculated body surface. The FF
resulted from calculating the ratio of ERPF and GFR. To identify
hypertensive patients at risk of cardiovascular and, possibly, renal
morbidity, we measured urinary albumin excretion rate (UAE) in
this group. UAE from two separate 24-hour urine collections was
measured using a immunonephelometric assay (Boehringer
Mannheim, Germany). Each urine sample was tested for urine
infection by microscopic examination of the sediment and by
culture. If infection was detected urine was sampled again once it
resolved and examined. The subjects were told to continue their
regular diet and treatment and to avoid heavy exercise on the days
of urine collection. The values represent the average of the two
different measurements. Microalbuminuria was defined as urinary
albumin excretion rate between 20 and 200 mg/min.
Detection of angiotensin converting enzyme genotype
DNA was extracted from peripheral blood leukocytes as de-
scribed previously [22]. In 18 of the 37 patients from protocol 1,
where blood samples were not available, DNA was extracted
directly from the paraffin-embedded renal tissues following stan-
dard methods [22]. It has been demonstrated that in this case,
polymerase chain reaction (PCR) of DNA from fixed, paraffin-
embedded tissues provides a relatively simple and extremely
sensitive method. The ACE I/D genotype was determined by PCR
using published primers 59-CTG GAG ACC ACT CCC ATC CTT
TCT-39 and 59GAT GTG GCC ATC ACA TTG GTC AGA T-39
that flank the polymorphic region [8]. PCR was conducted in 25 ml
volume containing 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl
pH 8.3, 200 mM of each dNTP, 1 mM primers, 1U Taq polymerase
and 100 ng of genomic DNA. After an initial denaturation at 96°C
for five minutes, thermocycling consisted of denaturation at 94°C
for 30 seconds, annealing at 58°C for 30 seconds, and extension at
72°C for one minute for 35 cycles followed by a final extension for
five minutes. Amplification products were separated on 0.5%
agarose/2.5% Nu Sieve (Amersham, Arlington Heights, IL, USA)
and visualized by ultraviolet transillumination after ethidium
bromide staining. This primer pair produced a '490 bp product
corresponding to the insertion and/or a '190 bp fragment corre-
sponding to the deletion. Subjects were classified as II, DD or
heterozygote for insertion/deletion (DI). Mistyping of DI het-
erozygotes as DD due to preferential amplification of the D allele
and inefficiency in amplification of the I allele has been described
[23]. Therefore, all samples found to be DD were amplified with
an insertion-specific primer pair that recognizes the inserted
sequence: 59-TGG GAC CAC AGC GCC CGC CAC TAC-39 and
59-TCG CCA GCC CTC CCA TGC CCA TAA-39 [19], with
identical PCR conditions except for an annealing temperature of
64°C. The reaction yields a 335 bp product in the presence of an
I allele.
Statistical analysis
Quantitative variables are expressed as mean 6 SEM. Genotype
distribution and allele frequencies were compared between
groups using the x2 test or the Fisher’s exact test. Differences
between quantitative variables were analyzed by parametric test
(analysis of variance). Only when the distribution was not normal
(UAE rate) a non-parametric test (Kruskal-Wallis) was per-
formed. A P value of less than 0.05 was considered significant.
RESULTS
Protocol 1
The group of patients from protocol 1 included 35 men and two
women, aged 42 6 one year with systolic blood pressure (SBP) of
169 6 5 and diastolic blood pressure (DBP) of 105 6 2 mm Hg at
the time of diagnosis, serum creatinine of 327 6 40 mmol/liter
(3.69 6 0.5 mg/dl) and with 1.97 6 0.5 g/day proteinuria. The
mean duration of known hypertension prior to the biopsy was 5 6
1 year, with a mean treated SBP of 147 6 2.5 and DBP 91 6 2 mm
Hg. The distribution of the ACE genotype in the nephroangio-
sclerosis group was 21 (57%) patients with DD genotype, 10
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(27%) with DI and 6 (16%) patients with II genotype (Table 1).
This distribution was clearly different to the one in the control
group, where the ACE genotype distribution was: 19 DD (25%),
48 DI (64%) and 8 II (11%; P 5 0.001). The hypertensive patients
with histological evidence of nephroangiosclerosis were also char-
acterized by an excess in the frequency of the D allele (70%),
while in the control group was only present in 57% (P , 0.05;
Table 1).
Protocol 2
The 75 hypertensive patients from protocol 2 included 30 male
and 45 female, aged 55 6 1 year, with SBP of 182 6 2.5 and DBP
of 109 6 1.1 mm Hg at the time of diagnosis. The mean creatinine
level was 76 6 2 mmol/liter (0.9 6 0.02 mg/dl) and the mean
duration of hypertension was 10 6 1 year with a mean treated SBP
of 142 6 1.5 and DBP of 88.6 6 1 mm Hg. Microalbuminuria was
detected in 14 patients (19%) and the mean urinary albumin
excretion rate was 19.6 6 12.5 mg/min. The renal hemodynamic
study disclosed a GFR of 98 6 4 ml/min/1.73 m2 and a ERPF of
438 6 13 ml/min/1.73 m2, resulting in a FF of 0.22, not signifi-
cantly different from the normal values of the laboratory.
The genotype distribution in hypertensive patients, 25 DD
(33%), 44 DI (59%) and 6 II (8%), was not significantly different
from that of the control group. The allele frequencies were also
not different between the two groups, with 94 (63%) allele D and
56 (37%) allele I in the hypertensive patients and 86 (57%) allele
D and 64 (43%) allele I in the control group. By using more
stringent inclusion criteria, that is, early onset of the disease
(age # 40 years) or higher BP levels (BP $ 180/110), the genotype
distribution was neither significantly different between hyperten-
sive and control subjects (data not shown). There was no differ-
ence in the genotype distribution between males and females
(data not shown).
No differences in age, BP level, known duration of hyperten-
sion, microalbuminuria and UAE rate were found between any of
the different ACE genotypes (Table 2). Similarly, plasma renin
activity and the renal hemodynamic parameters measured in
hypertensive patients were similar among the three genotypes
(Table 2).
DISCUSSION
The kidney is a main target organ in EH. In early stages of this
disease, functional changes due to an increase of renal vascular
resistance, with reduction in RPF, normal or subnormal GFR
accompanied by raised FF, are observed in many patients [24].
Late in the course of the disease, GFR decreases probably due to
loss of functioning nephrons, representing the onset of irrevers-
ible morphologic damage due to nephroangiosclerosis [24]. There
are several mechanisms, both hemodynamic and non-hemody-
namic, involved in the development of these alterations, and there
is agreement about the important role of the RAS in this process
[3]. On the other hand, there is an individual susceptibility to
develop end-stage renal disease due to hypertension which, in
some patients, occurs even after a good control of their hyperten-
sion has been achieved [7]. Differences in the activation of the
renal tissue RAS, not detectable by clinical tests, could explain the
differences in the incidence of renal insufficiency among hyper-
tensive patients.
The I/D polymorphism of the ACE gene has been associated in
some studies [12, 13] but not in others [14, 15] with various forms
of cardiovascular disease. More recently, although this polymor-
phism has not yet been associated with primary forms of renal
disease, it has been closely linked to the progression of chronic
renal diseases of different etiologies [19, 20]. However, the I/D
polymorphism has not yet been investigated in proven hyperten-
sive renal disease. The present study shows a significant associa-
tion between the ACE DD genotype and the presence of biopsy-
proven nephroangiosclerosis in EH that, to our knowledge, has
not been reported before. The histological vascular renal changes
observed in hypertension, particularly segmental hyalinosis within
afferent arterioles and interlobular arteries, has also been de-
scribed as a phenomenon of aging, as a feature of diabetic
nephropathy and as a vascular complication of cyclosporine
therapy [21]. Nevertheless, it has been shown that the vascular
changes on the renal segmentary arteries usually do not appear
before the age of 50 years, which was the cut-off age in our study.
In addition, none of the patients we included had diabetes
mellitus nor had they received cyclosporine. Although the clinical
Table 1. ACE genotype distribution and allele frequency in the hypertensive patients with nephroangiosclerosis from protocol 1 and in the control
group
Genotypesa Allele frequencyb
DD DI II Total D I Total
Nephroangiosclerosis 21 (57%) 10 (27%) 6 (16%) 37 52 (70%) 22 (30%) 74
Controls 19 (25%) 48 (64%) 8 (11%) 75 86 (57%) 64 (43%) 150
x2 tests were performed for nephroangiosclerosis vs. controls for analyses of genotype distributions and allele frequencies.
a P , 0.001, b P , 0.05
Table 2. Clinical and renal features of hypertensive patients from
protocol 2 grouped by genotype
DD DI II P
N 25 (33%) 44 (59%) 6 (8%)
Age years 56 6 1.4 55 6 1.4 47 6 3 NS
Sex M/F 10/15 17/27 3/3 NS
SBP mm Hg 178 6 3 188 6 4 186 6 11 NS
DBP mm Hg 111 6 2.5 109 6 2 107 6 5 NS
PRA ng z ml21 z hr21 0.56 6 0.15 0.43 6 0.08 0.25 6 0.15 NS
Duration of HT years 9 6 1 11 6 1 8 6 2 NS
Microalbuminuria 7 (50%) 6 (43%) 1 (7%) NS
UAE rate mg/min 30 6 14 15 6 5 5.3 6 1.5 NS
GFR ml/min/1.73 m2 104 6 5 92 6 7 100 6 2 NS
ERPF ml/min/1.73 m2 434 6 12 420 6 14 522 6 2 NS
Abbreviations are: NS, not significant; M, male; F, female; SBP, systolic
blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity;
HT, hypertension; UAE, urinary albumin excretion; GFR, glomerular
filtration rate; ERPF, effective renal plasma flow. One-way ANOVA was
performed to compare group means for different parameters.
Ferna´ndez-Llama et al: ACE polymorphism and nephroangiosclerosis 1745
and pathological diagnosis of nephroangiosclerosis was fairly
unequivocal in our patients, it has to be considered that the
presence of proteinuria with a normal sediment in a patient with
essential hypertension is not a routine indication of renal biopsy.
Therefore, in spite of the striking association found between the D
allele with nephroangiosclerosis, our retrospective sample of
patients with nephroangiosclerosis may not be representative of
the general hypertensive population with milder clinical presen-
tations of kidney organ damage. Although there is a clear
predominance of males in our nephroangiosclerosis group, a
difference in the distribution of genotypes among sex groups has
not been observed in this or any other study.
In a separate protocol, we investigated the functional renal
profile of a group of hypertensives. It is a widely accepted notion
that microalbuminuria in essential hypertensive patients may be
secondary to the renal functional abnormalities that accompany
hypertension. ACE inhibition has been demonstrated to be effec-
tive in reducing the urinary excretion of albumin in several
diseases [18], but it has been difficult to prove a relationship
between microalbuminuria and specific changes in the renal
hemodynamics observed in some patients with EH [25]. Although
microalbuminuria is not completely proven to be a risk factor for
the future development of proteinuria and worsening of renal
function in nondiabetic patients with EH, there is evidence
indicating that it is a marker of increased cardiovascular risk in
these patients [26]. Interestingly, an association between the D
allele of the ACE gene with microalbuminuria [27, 28] as well as
retinopathy and left ventricular hyperthrophy has recently been
reported, with results suggesting that the deletion polymorphism
might be an independent risk factor for the development of organ
damage in hypertensive patients [27].
The lack of association between ACE I/D polymorphism and
BP observed in our study is in agreement with most reported data
[14] and supports the notion that the mechanisms of kidney
damage by the RAS may be mediated by mechanisms probably
additive to the pressor, hemodynamic effect. In protocol 2 we
were not able to demonstrate any relation between renal func-
tional parameters and the ACE genotype, probably because these
parameters were within the normal range in our hypertensive
patients. Similarly, the distribution of genotypes was not different
between hypertensives with or without microalbuminuria, proba-
bly due to the low number of patients with this abnormality. We
can only speculate about the possible link between the DD
genotype of the ACE gene with the presence of renal damage in
hypertension. The ACE I/D polymorphism has been associated to
both plasma and tissue ACE levels, the DD genotype being the
one related to the highest levels and the II to the lowest [10]. It
has been assumed that the tissue ACE levels determine the local
production of angiotensin II. Since all the components of the RAS
have been detected in the kidney [3], subjects with the DD
genotype might have higher local activity of ACE and higher
levels of angiotensin II that could lead to increased intraglomeru-
lar pressure, stimulate different proto-oncogenes and growth
factors inducing cell hypertrophy and proliferation, and increases
in cell matrix protein. It is important to note that a molecular
variant of the ACE gene determines plasma ACE activity in
congenic strains of rats, demonstrating that a quantitative trait
locus confers concordant effects in humans and rats [29]. How-
ever, data from a family study suggest that the I/D polymorphism
may be in fact a genetic marker strongly associated with an
unknown functional variant (ACE S/s) [30] located within or near
the ACE gene and which explains a large portion of the interin-
dividual variance of plasma ACE levels. Therefore, the molecular
mechanism by which variants in the ACE gene may influence
target organ damage in hypertension is still unknown.
In conclusion, the present study demonstrates the presence of
an association between the I/D polymorphism of the ACE gene
with biopsy-proven renal involvement occurring in hypertensive
patients. This suggests that genetic factors may be important in
determining the renal damage observed in patients with essential
hypertension and that the DD genotype of the ACE gene could be
a useful genetic marker with important clinical, therapeutic and
prognostic implications in recognizing hypertensive subjects that
are at greater risk of renal damage. However, larger prospective
studies will be necessary to assess the role of the DD genotype in
the renal outcome in essential hypertensive patients with and
without renal involvement.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; BP, blood pressure; DBP, diastolic blood pressure; EH, essential
hypertension; ERPF, effective renal plasma flow; FF, filtration fraction;
GFR, glomerular filtration rate; I/D, insertion/deletion; PCR, polymerase
chain reaction; RAS, renin-angiotensin system; SBP, systolic blood pres-
sure; UAE, urinary albumin excretion rate.
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